Epclusa

Gilead Sciences, Inc

Revision date : 2016-09-23

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
Health risk rating
Safety risk rating
Environmental risk rating

Note: Ingredients listed on restricted chemical lists

EC/CAS

232-674-9/9004-34-6

Name of the chemical

cellulose

Concentration

30-40%

EC/CAS

236-675-5/13463-67-7

Name of the chemical

Reaction mass of titanium dioxide and silver chloride

Concentration

0.3-0.9%

EC/CAS

209-150-3

Name of the chemical

Aluminium, zinc, magnesium and calcium stearates

Concentration

1-2%

General Information

Revision date

2016-09-23

Product name

Epclusa

Product Synonyms

SOF/VEL Tablets

Chemical name

Mixture

1.2.1 Relevant identified uses

Bulk formulated pharmaceutical mixture/Formulated pharmaceutical product/ mixture packaged in final form for patient use and uses advised against

Emergency telephone

+1 (800) 424-9300, +1 (703) 527-3887

Icons in SDS

Company Information

company name

Gilead Sciences, Inc

e-mail address of the competent person responsible for the Safety Data Sheet

msdscoordinator@gilead.com

GHS Information

Signal word

None required

Section 2

SECTION 2: Hazards identification

WHMIS 2015 Classification of the substance or mixture Drugs in the finished state and intended for the final user are not subject to labeling in the US, EU or Canada. Consult prescribing/packaging information The classification and labeling listed below is for bulk drug product Globally Harmonized System [GHS] Not classified

Hazard pictograms

None required

Signal word

None required SECTION 2 - HAZARDS IDENTIFICATION …continued

Hazard statements

None required

Precautionary statements

None required

2.3 Other hazards

Coadministration of the single agents SOF 400 mg and Velpatasvir 25mg or 100 mg for up to 12 weeks was well tolerated in over 800 HCV infected patients in Phase 2 studies. There was a low rate of treatment discontinuation for adverse events (AE). There was a low incidence of serious adverse events, of severe or life-threatening AEs and of Grade 3 and 4 laboratory abnormalities. Note This mixture does not meet criteria for classification under GHS as implemented

2.1 Classification of the substance or mixture

Drugs in the finished state and intended for the final user are not subject to substance or mixture

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.